Versa Vascular

Executive Summary

Versa Vascular is a private medical device company headquartered in Santa Cruz, California, developing a novel minimally invasive solution for tricuspid valve repair. Founded in 2020, the company addresses the significant unmet clinical need in patients with severe tricuspid regurgitation (TR). TR is a progressive condition associated with poor prognosis and limited treatment options, especially for patients who are not candidates for open-heart surgery. Versa's technology is designed to work with native leaflet function to improve blood flow, potentially offering a safer and more effective alternative to existing transcatheter therapies. The company is still in early stages of development, with no disclosed funding rounds or regulatory milestones, but its focus on a high-growth cardiovascular niche positions it for attention from strategic partners and investors. The global tricuspid valve repair market is expected to grow rapidly as awareness and diagnosis improve, yet only a few competitors have gained FDA approval. Versa Vascular's approach aims to simplify the procedure and broaden the patient population eligible for intervention. While the company has not publicly shared clinical data or regulatory timelines, its technology platform suggests potential advantages in durability and ease of use. The key near-term milestones include completing preclinical studies, initiating first-in-human trials, and securing series A financing to support clinical development. Given the early stage, conviction in Versa Vascular is moderate pending further de-risking events.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement60% success
• Q1 2027First-in-Human Clinical Trial Initiation50% success
• Q4 2026FDA Breakthrough Device Designation70% success